CLDN 18.2-targeting radiotherapeutic (Full-Life Technologies)

N/A

Report date: 2025/06/11 10:57:51
NME

Base Information

Drug NameCLDN 18.2-targeting radiotherapeutic (Full-Life Technologies)
Drug Alias NameN/A
ClassificationSmall moleculesRadiation-emitting products > Radioactive therapeutic agent
Mechanisms of ActionClaudin 18 protein modulators
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungPancreatic NeoplasmsStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesFull Life Technologies Ltd
China Registration ClassN/A

Develop Information

Active CompaniesFull Life Technologies Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungPancreatic NeoplasmsStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A